AI summary by TwinMind
Why Gene Therapy is So Expensive
Asianometry
19m 29s
Introduction to Gene Therapy Complexity
- Gene therapies = most expensive drugs in world
- Producing viral vectors for in-vivo gene therapy = most complicated process ever attempted at scale in bio-pharmaceuticals
- Goal: transfer genetic material to target cells to add, suppress, or edit genes
- Vehicles for gene delivery called vectors
Early Non-Viral Gene Transfer Methods (1960s-1980s)
- 1962: Polish-American scientist Vox CLA Silasi & Elizabeth Obasa pioneered gene transfer method
- Used famous HeLa cell line to test if mammalian cells can pass foreign genes to next generation
- Problem: both genes and cell membranes negatively charged
- Solution: calcium phosphate co-precipitation method
- Added positively charged calcium ions to DNA
- Reduced negative charge enough for cell entry
- Widely used as vector in lab setting 1970s-1980s
- Impractical for in-vivo gene therapy treatments:
- Inefficient even in controlled lab conditions
- No targeting mechanism for specific cells in body
- DNA physically fragile, deteriorates in blood/tissue environment
- Calcium phosphate triggers immune responses or clumps together
Discovery of Viral Gene Transfer (1950s-1960s)
- Viruses known to carry genes since early 1950s
- 1952: Norton Zinder & Nobel Prize winner Joshua Lederberg published experiment
- Discovered small particles can move traits between Salmonella bacteria populations
- Concluded agent was virus due to tiny size and antibiotic resistance
- Named process "transduction"
- 1966: Nobel Prize winner Edward Tatum's speech first publicly proposed using modified viruses for healing genes
- Suggested DNA transformation/transduction could work with animal cells
- Would facilitate mammalian somatic cell genetics development
- Bring closer to successful genetic engineering
First Human Gene Therapy Trials (1970s)
- Mid-1970s: Two girls in West German village with rare genetic defect
- Bodies couldn't produce arginase enzyme
- Arginase breaks down arginine; excess causes seizures and mental retardation
- Professor E. Stanfield Rogers at Oak Ridge Lab worked with Shope papilloma virus
- Infected rabbits grew horns on faces/necks
- Also produced elevated amounts of different arginase type
- Lab workers accidentally infected showed similar results
- Rogers proposed injecting girls with Shope virus
- Trial failed: only created severe but temporary allergy in one child
- Later genome sequencing revealed virus had no arginase gene for humans
- Effects likely from heightened immune response to virus
First Successful Gene Therapy (1990)
- September 1990: FDA approved first gene therapy trial for therapeutic effect
- Two girls with severe combined immunodeficiency (SCID) - "Bubble Boy syndrome"
- Deficiency in adenosine deaminase
- Previously, infants died within first 2 years of life
- Team led by Michael Blaese used retrovirus-based treatment
- Extracted T-cells from girls
- Used disabled Moloney murine leukemia retrovirus to inject new genes
- Modified cells injected back into girls' bone marrow
- Girls received multiple infusions over 2 years
- After 5 years: one girl showed T-cell count recovery, other minimal effects
- No serious negative side effects
- Difficult to determine if genetic therapy worked (patient also received enzyme therapy)
- Experiment seen as major step forward, opened door to other SCID gene therapy trials
Retrovirus Challenges and Safety Concerns
- Early therapies used retroviruses (RNA viruses with reverse transcriptase)
- Initially chosen for ability to insert genes into cell genome
- Industry moved away due to limitations:
- Only target dividing cells (most vulnerable to intrusion)
- Limited to stem cell therapies like T-cells for SCID
- Safety concerns: insertional mutagenesis risk
- Gene insertion can disrupt other genes
- Can activate cancer-causing oncogenes
- 2008 paper: 10 SCID patients received gene therapy
- 9 treatments successful
- 4 of 9 patients developed leukemia few years after treatment
Adenovirus Vectors: Benefits and Tragic Failure
- Adenoviruses emerged as potential replacement for retroviruses
- Large double-stranded viruses causing common cold to serious diseases
- Advantages over retroviruses:
- Much larger capacity: 36,000 base pairs DNA vs 8,000 for retroviruses
- Don't require dividing cells for infection (expanded target range)
- Genes remain episomal (separate from genome like loose leaf paper)
- Minimized cancer risks
- Major risk: immunogenic (trigger big immune response)
Jesse Gelsinger Tragedy (1999)
- 18-year-old Jesse Gelsinger signed up for University of Pennsylvania trial
- Had mild OTC deficiency (affects body's ability to break down ammonia)
- Condition manageable with diet and pills
- Received adenovirus-based gene treatment
- Vector transferred <1% of desired genes to right cells
- Given highest dose: 38 trillion viral particles
- Virus had genes removed (couldn't replicate) but still immunogenic
- Large dose triggered massive immune response and multi-organ failure
- Gelsinger died
- Serious lapses discovered: trial protocol violations, financial conflicts, informed consent issues
- Lawsuits filed
- Largely ended adenovirus use for most gene therapies in US
- Still used for cancer therapies where immunogenic status is beneficial
First Approved Gene Therapy (2003)
- 2003: China's State Food and Drug Administration approved Gendicine
- Adenovirus cancer therapy for head and neck cancers
- Neither US nor EU approved it
Lentivirus Development
- Industry adopted new viral vectors post-tragedy with renewed safety focus
- Lentiviruses = subset of retroviruses (HIV is lentivirus)
- Small size and sustained gene expression ability
- Top choice for ex-vivo cell treatments (cells treated outside body then returned)
- Great benefit for X-linked adrenoleukodystrophy (ALD) treatment
- Characterized by fatty acid buildup in nervous system
- Can lead to vegetative state and death
- Featured in 1992 movie "Lorenzo's Oil"
- 2007: first gene therapy trials for ALD
- FDA granted breakthrough status to several treatments
- Retrovirus oncogene activation threat remains
Adeno-Associated Viruses (AAVs): Current Standard
- Most therapies moved to modified adeno-associated viruses (AAVs)
- Discovered 1960s as contaminants in adenovirus cell lines
- Key characteristics:
- Very small: ~25 nanometers wide
- Hold far fewer DNA: up to 5,000 bases (newer versions under development for higher capacity)
- Cannot replicate without helper functions from adenoviruses
- Travel with adenoviruses like "parasite to a virus"
- Never seen to cause disease
- Generally don't cause toxicity or immunogenic issues (unless repeatedly administered)
- Scientists started working with them mid-1980s
- Can hang around like drone until able to inject payload
- First AAV trials 1990s targeted cystic fibrosis gene (success remains elusive)
First AAV Approval: Glybera (2012)
- EU approved Glybera 2012 after 3 prior rejections
- Treatment for lipoprotein lipase deficiency
- Gained negative press for costing over $1 million
- Later withdrawn - only 31 people ever received drug
Current AAV Manufacturing Challenges
- 200+ trials in progress for AAVs (dominant platform)
- Applicable to other virus vectors like lentiviruses
- Astoundingly complicated to produce due to stripped-down nature
Upstream Processes
- Produce raw viruses in mass
- Coordinate expression of 10+ virus genes from AAV and co-infection viruses
- Amplify therapeutic gene payload accurately in high volume
- Ensure sufficient quantities of all components
- Assemble components inside host cells:
- Usually embryonic kidney cell line HEK 293
- Or insect cells
- Transfect host cells with components
- Ferment cells in bioreactors 48-72 hours
- Assembly process inside host cells poorly understood
- Cannot easily optimize process
Poor Yields
- Yields remain very low
- Majority of host cell production = empty capsids (protein envelopes without genes)
- <10,000 complete viruses produced per batch
- Yield only 5-30% of total production
- Only percentage of complete viruses actually infectious
- Per 2023 paper: very disappointing results
Downstream Processes
- Extract and purify AAVs to meet FDA standards
- Harvest host cells (may require lysis to release AAV particles)
- Filter out impurities:
- Cell debris
- Empty capsids
- Host cell DNA strands
- Other contaminants
- Multi-step purification process:
- Filters and ultracentrifugation (>150,000 RPM to separate by weight)
- Series of chromatography steps (separate by charge, hydrophobicity, size)
- Purify results and formulate for stability
- Extensive downstream processes further reduce yields
- Necessary to ensure dose safety and efficacy
Economic Challenges
- Gene therapy costs $1+ million per treatment
- Multiple factors contribute to high costs:
- Rigorous regulation (makes sense given history)
- Small patient populations
- Pool shrinks if therapy successful
- Primary cost driver: manufacturing
- Doses cost $300K+ to manufacture
- Each production run yields <20% usable virus
- Can't scale up batches (risk losing consistency)
- Single dose may require up to dozen runs or parallelization
- Many gene therapy companies struggle to turn profit despite high prices
Future Manufacturing Needs
- Industry searching for rapid, high-throughput viral manufacturing platform
- Need quality monitoring systems like semiconductor fabs
- Opportunity exists but strict regulation and conservative industry nature makes adoption difficult
- Long-term economic sustainability of $1-3 million price tags questionable
- Changes may be forced upon industry soon
